Background: Although post-stroke depression is widely recognized, less is known about depressive symptoms in the acute stage of stroke and especially in young stroke patients. We thus investigated depressive symptoms and their determinants in such a cohort. Methods: The Stroke in Young Fabry Patients study (sifap1) prospectively recruited a large multinational European cohort (n = 5,023) of patients with a cerebrovascular event aged 18-55. For assessing clinically relevant depressive symptoms (CRDS, defined by a BDI-score ≥18) the self-reporting Beck Depression Inventory (BDI) was obtained on inclusion in the study. Associations with baseline parameters, stroke severity (National Institutes of Health Stroke Scale, NIHSS), and brain MRI findings were analyzed. Results: From the 2007 patients with BDI documentation, 202 (10.1%) had CRDS. CRDS were observed more frequently in women (12.6 vs. 8.2% in men, p < 0.001). Patients with CRDS more often had arterial hypertension, diabetes mellitus, and hyperlipidemia than patients without CRDS (hypertension: 58.0 vs. 47.1%, p = 0.017; diabetes mellitus: 17.9 vs. 8.9%, p < 0.001; hyperlipidemia: 40.5 vs. 32.3%, p = 0.012). In the subgroup of patients with ischemic stroke or TIA (n = 1,832) no significant associations between CRDS and cerebral MRI findings such as the presence of acute infarcts (68.1 vs. 65.8%, p = 0.666), old infarctions (63.4 vs. 62.1%, p = 0.725) or white matter hyper-intensities (51.6 vs. 53.7%, p = 0.520) were found. Conclusion: Depressive symptoms were present in 10.1% of young stroke patients in the acute phase, and were related to risk factors but not to imaging findings.

1.
Andersen G, Vestergaard K, Riis J, Lauritzen L: Incidence of post-stroke depression during the first year in a large unselected stroke population determined using a valid standardized rating scale. Acta Psychiatr Scand 1994;90:190-195.
2.
Kotila M, Numminen H, Waltimo O, Kaste M: Depression after stroke: results of the FINNSTROKE Study. Stroke 1998;29:368-372.
3.
Astrom M, Adolfsson R, Asplund K: Major depression in stroke patients. A 3-year longitudinal study. Stroke 1993;24:976-982.
4.
Hackett ML, Anderson CS, House AO: Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 2005;36:1098-1103.
5.
Sienkiewicz-Jarosz H, Milewska D, Bochynska A, Chelmniak A, Dworek N, Kasprzyk K, Galecka K, Szczepanska-Szarej A, Chwojnicki K, Zyluk B, Slowik A, Ryglewicz D: Predictors of depressive symptoms in patients with stroke - a three-month follow-up. Neurol Neurochir Pol 2010;44:13-20.
6.
Hackett ML, Hill KM, Hewison J, Anderson CS, House AO: Stroke survivors who score below threshold on standard depression measures may still have negative cognitions of concern. Stroke 2010;41:478-481.
7.
Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, Kaste M, Tatlisumak T: Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 2009;40:1195-1203.
8.
Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, Bottcher T, Heuschmann PU, Tatlisumak T, Tanislav C, Jungehulsing GJ, Giese AK, Putaala J, Huber R, Bodechtel U, Lichy C, Enzinger C, Schmidt R, Hennerici MG, Kaps M, Kessler C, Lackner K, Paschke E, Meyer W, Mascher H, Riess O, Kolodny E, Norrving B: Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke 2013;44:340-349.
9.
European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
10.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
11.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
12.
Fazekas F, Enzinger C, Schmidt R, Dichgans M, Gaertner B, Jungehulsing GJ, Hennerici MG, Heuschmann P, Holzhausen M, Kaps M, Kessler C, Martus P, Putaala J, Ropele S, Tanislav C, Tatlisumak T, Norrving B, Rolfs A: MRI in acute cerebral ischemia of the young: the Stroke in Young Fabry Patients (sifap1) Study. Neurology 2013;81:1914-1921.
13.
Tatu L, Moulin T, Bogousslavsky J, Duvernoy H: Arterial territories of the human brain: cerebral hemispheres. Neurology 1998;50:1699-1708.
14.
Hackett ML, Yapa C, Parag V, Anderson CS: Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330-1340.
15.
Morris PL, Robinson RG, Raphael B: Prevalence and course of depressive disorders in hospitalized stroke patients. Int J Psychiatry Med 1990;20:349-364.
16.
Nys GM, van Zandvoort MJ, van der Worp HB, de Haan EH, de Kort PL, Kappelle LJ: Early depressive symptoms after stroke: neuropsychological correlates and lesion characteristics. J Neurol Sci 2005;228:27-33.
17.
Snaphaan L, van der Werf S, Kanselaar K, de Leeuw FE: Post-stroke depressive symptoms are associated with post-stroke characteristics. Cerebrovasc Dis 2009;28:551-557.
18.
Hackett ML, Anderson CS: Predictors of depression after stroke: a systematic review of observational studies. Stroke 2005;36:2296-2301.
19.
Sharpe M, Hawton K, Seagroatt V, Bamford J, House A, Molyneux A, Sandercock P, Warlow C: Depressive disorders in long-term survivors of stroke. Associations with demographic and social factors, functional status, and brain lesion volume. Br J Psychiatry 1994;164:380-386.
20.
Wade DT, Legh-Smith J, Hewer RA: Depressed mood after stroke. A community study of its frequency. Br J Psychiatry 1987;151:200-205.
21.
Jafari F, Hadizadeh MH, Zabihi R, Ganji K: Comparison of depression, anxiety, quality of life, vitality and mental health between premenopausal and postmenopausal women. Climacteric 2014;17:660-665.
22.
Schiltz L, Ciccarello A, Ricci-Boyer L, Schiltz J: Defence mechanisms and coping strategies in men and women: a comparative and structural study based on the artistic production of people suffering from a break-up of their life project. Bull Soc Sci Med Grand Duche Luxemb 2013;2:7-24.
23.
Strohmaier J, Amelang M, Hothorn LA, Witt SH, Nieratschker V, Gerhard D, Meier S, Wust S, Frank J, Loerbroks A, Rietschel M, Sturmer T, Schulze TG: The psychiatric vulnerability gene CACNA1C and its sex-specific relationship with personality traits, resilience factors and depressive symptoms in the general population. Mol Psychiatry 2013;18:607-613.
24.
Firbank MJ, O'Brien JT, Pakrasi S, Pantoni L, Simoni M, Erkinjuntti T, Wallin A, Wahlund LO, van Straaten I, Inzitari D: White matter hyperintensities and depression - preliminary results from the LADIS study. Int J Geriatr Psychiatry 2005;20:674-679.
25.
Hajjar I, Quach L, Yang F, Chaves PH, Newman AB, Mukamal K, Longstreth W Jr, Inzitari M, Lipsitz LA: Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation 2011;123:858-865.
26.
Iosifescu DV, Renshaw PF, Dougherty DD, Lyoo IK, Lee HK, Fraguas R, Cassano P, Nierenberg AA, Fava M: Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities. J Nerv Ment Dis 2007;195:175-178.
27.
Jorm AF, Anstey KJ, Christensen H, de Plater G, Kumar R, Wen W, Sachdev P: MRI hyperintensities and depressive symptoms in a community sample of individuals 60-64 years old. Am J Psychiatry 2005;162:699-705.
28.
Serafini G, Pompili M, Innamorati M, Negro A, Fiorillo M, Lamis DA, Erbuto D, Marsibilio F, Romano A, Amore M, D'Alonzo L, Bozzao A, Girardi P, Martelletti P: White matter hyperintensities and self-reported depression in a sample of patients with chronic headache. J Headache Pain 2012;13:661-667.
29.
Versluis CE, van der Mast RC, van Buchem MA, Bollen EL, Blauw GJ, Eekhof JA, van der Wee NJ, de Craen AJ: Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease: The PROSPER Study. Int J Geriatr Psychiatry 2006;21:375-381.
30.
Kim JT, Park MS, Yoon GJ, Jung HJ, Choi KH, Nam TS, Lee SH, Choi SM, Kim BC, Kim MK, Cho KH: White matter hyperintensity as a factor associated with delayed mood disorders in patients with acute ischemic stroke. Eur Neurol 2011;66:343-349.
31.
Spalletta G, Guida G, De Angelis D, Caltagirone C: Predictors of cognitive level and depression severity are different in patients with left and right hemispheric stroke within the first year of illness. J Neurol 2002;249:1541-1551.
32.
Dhamoon MS, Moon YP, Paik MC, Sacco RL, Elkind MS: Diabetes predicts long-term disability in an elderly urban cohort: the Northern Manhattan Study. Ann Epidemiol 2014;24:362-368.
33.
Benito-Leon J, Labiano-Fontcuberta A, Mitchell AJ, Moreno-Garcia S, Martinez-Martin P: Multiple sclerosis is associated with high trait anger: A case-control study. J Neurol Sci 2014;340:69-74.
34.
Grases G, Colom MA, Fernandez RA, Costa-Bauza A, Grases F: Evidence of higher oxidative status in depression and anxiety. Oxid Med Cell Longev 2014;2014:430216.
35.
Ramiro Fde S, Lombardi Junior I, da Silva RC, Montesano FT, de Oliveira NR, Diniz RE, Alambert PA, Padovani Rda C: Investigation of stress, anxiety and depression in women with fibromyalgia: a comparative study. Rev Bras Reumatol 2014;54:27-32.
36.
Uglesic B, Lasic D, Zuljan-Cvitanovic M, Bukovic D, Karelovic D, Delic-Brkljacic D, Bukovic N, Radan M: Prevalence of depressive symptoms among college students and the influence of sport activity. Coll Antropol 2014;38:235-239.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.